Pioglitazone Decreases Plasma Angiotensin II Concentration inType 2 Diabetes

Abstract

Aim:Adipocytes express all components of the renin-angiotensin system (RAS), and adipocyte RAS regulates adipocyte differentiation and metabolism. Plasma angiotensin (A ) is a putative marker of adipocyte RAS production. The aim of this study was to investigate the effect of pioglitazone on plasma A in type 2 diabetes (T2D). Methods: Fifty Japanese subjects with T2D were randomly allocated to two groups. One group was administered pioglitazone 30 mg/day (pioglitazone group) and the other group was not given pioglitazone (control group) for 16 weeks. Lipoprotein lipase mass in preheparin serum (LPL mass) was measured as an adipocyte-derived factor and a marker of insulin sensitivity. Results: In the pioglitazone group, the mean HbA1c decreased ( p 0.0001), LPL mass increased ( p 0.0001), and plasma A decreased ( p 0.0007), whereas these parameters were unchanged in the control group. The change in plasma A correlated negatively with the change in LPL mass (r 0.312) in the pioglitazone group. In the pioglitazone group, the decrease in plasma A was higher ( p 0.0002) and the increase in LPL mass tended to be higher ( p 0.0941) in the subgroup with higher baseline plasma A than that with lower plasma A . Conclusions: The present study indicates that pioglitazone decreases plasma A associated with an increase in LPL mass in T2D. The insulin-sensitizing effect of pioglitazone may be involved in suppressing adipocyte RAS. J Atheroscler Thromb, 2010; 17:651-657.

Decreased Triglyceride and Increased Serum Lipoprotein Lipase Levels Are Correlated to Increased High-Density Lipoprotein-Cholesterol Levels after Laparoscopic Sleeve Gastrectomy

“…Previous studies have shown an increase in pre-heparin LPL levels after biguanides and thiazolidinediones use [20,21]. In this study, a significant decrease in the use of biguanides, thiazolidinediones, sulfonylureas, dipeptidyl peptidase-4, and sodium-glucose cotransporter-2 inhibitor was observed post-LSG (p = 0.0003, 0.0351, 0.0007, 0.0469, and 0.0401, respectively) (shown in Table 2).…”

Increased cord blood angiotensin II concentration is associated with decreased insulin sensitivity in the offspring of mothers with gestational diabetes mellitus

“…26,27 Pioglitazone, an insulin-sensitizing thiazolidinedione agent, can decrease plasma Ang II concentration in patients with T2DM. 28 In conclusion, increased Ang II concentration is associated with decreased insulin sensitivity in adults with obesity or/and T2DM. And from our study, this has also been demonstrated in the fetuses of mothers with GDM at birth.…”

Effects of PPARγAgonist Pioglitazone on Redox-Sensitive Cellular Signaling in Young Spontaneously Hypertensive Rats

“…It has been shown that RSG decreases both angiotensinogen protein expression and angiotensin II release in isolated human subcutaneous adipocytes [39]. In addition, it was reported that PIO treatment decreases serum angiotensin II level in type 2 diabetes patients [40]. The above facts lead us to study the expression of adipose tissue RAS components under PIO treatment.…”